...
首页> 外文期刊>BMC Medical Genetics >Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
【24h】

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy

机译:胃肠道意外参与1型Gaucher病的病例报告:依格司他酒石酸盐治疗和酶替代疗法的比较

获取原文
           

摘要

Background Gastrointestinal involvement in Gaucher disease is very rare, and appears to be unresponsive to enzyme replacement therapy (ERT). Case presentation Here, we describe identical twin, splenectomized, non-neuronopathic Gaucher patients on long-term ERT for 9?years, who complained of epigastric discomfort due to Gaucher cell infiltration of the gastroduodenal mucosa. Rare compound heterozygous mutations (p.Arg48Trp and p.Arg257Gln) of the GBA gene were found in both. Improvement in the gastroduodenal infiltration and reduced chitotriosidase levels were observed in one who switched to eliglustat tartrate for 1?year, whereas the other one who maintained ERT showed no improvement of chitotriosidase level and persistent duodenal lesions. Conclusion This shows that eliglustat might be an effective treatment for Gaucher disease patients having lesions resistant to ERT.
机译:背景胃肠道参与高雪氏病非常罕见,并且似乎对酶替代疗法(ERT)没有反应。病例介绍在这里,我们描述了长期接受ERT长达9年的同卵双生,脾切除术,非神经病变的Gaucher患者,他们抱怨由于胃十二指肠粘膜的Gaucher细胞浸润而引起上腹部不适。两者中均发现了GBA基因的罕见复合杂合突变(p.Arg48Trp和p.Arg257Gln)。一位改用酒石酸依格鲁司汀治疗1年的患者,观察到十二指肠胃浸润的改善和壳三糖苷酶水平的降低,而另一位维持ERT的患者未显示壳三糖苷酶水平和持续的十二指肠病变。结论这表明依格鲁司他可能是治疗对ERT有抵抗力的高雪氏病患者的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号